GSK PLC Sponsored ADR $GSK Shares Sold by Miller Howard Investments Inc. NY

Miller Howard Investments Inc. NY lowered its position in GSK PLC Sponsored ADR (NYSE:GSK) by 0.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,629,351 shares of the pharmaceutical company’s stock after selling 12,763 shares during the period. GSK comprises 2.5% of Miller Howard Investments Inc. NY’s holdings, making the stock its 5th largest position. Miller Howard Investments Inc. NY owned 0.08% of GSK worth $89,924,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GSK. First Horizon Corp lifted its holdings in shares of GSK by 78.7% in the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 236 shares in the last quarter. Elyxium Wealth LLC bought a new position in shares of GSK during the fourth quarter worth about $30,000. Triumph Capital Management bought a new position in shares of GSK during the third quarter worth about $40,000. 1248 Management LLC lifted its position in shares of GSK by 314.6% in the third quarter. 1248 Management LLC now owns 1,053 shares of the pharmaceutical company’s stock worth $46,000 after purchasing an additional 799 shares in the last quarter. Finally, Coston McIsaac & Partners boosted its holdings in GSK by 17.3% during the fourth quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock worth $68,000 after purchasing an additional 206 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GSK shares. Weiss Ratings cut GSK from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 11th. Royal Bank Of Canada reiterated an “outperform” rating on shares of GSK in a report on Tuesday, June 9th. Finally, Wall Street Zen cut GSK from a “buy” rating to a “hold” rating in a research report on Saturday, May 30th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, GSK currently has a consensus rating of “Hold” and a consensus target price of $53.00.

GSK Stock Performance

Shares of GSK stock opened at $52.09 on Wednesday. GSK PLC Sponsored ADR has a 52 week low of $35.45 and a 52 week high of $61.69. The company has a market capitalization of $105.49 billion, a price-to-earnings ratio of 13.54, a PEG ratio of 2.62 and a beta of 0.36. The company has a 50-day simple moving average of $52.39 and a 200 day simple moving average of $52.89. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.52 and a current ratio of 0.79.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Stockholders of record on Friday, May 15th will be issued a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Friday, May 15th. GSK’s payout ratio is currently 47.01%.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.